

Glyceryl Diesters

Preethi S. Raj*, Wilma F. Bergfeld**, Donald V. Belsito**,
David E. Cohen**, Curtis D. Klaassen**, Daniel C. Liebler***,
Allan E. Rettie**, David Ross**, Thomas J. Slaga**, Paul W. Snyder**,
Susan Tilton**, Monice Fiume†, and Bart Heldreth‡

International Journal of Toxicology
2023, Vol. 42(Supplement 3) 40S–44S
© The Author(s) 2023
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/10915818231204269
journals.sagepub.com/home/ijt



Abstract

The Expert Panel for Cosmetic Ingredient Safety reviewed newly available studies since their original assessment in 2002, along with updated information regarding product types and concentrations of use, and confirmed that these 17 glyceryl diesters are safe as cosmetic ingredients in the practices of use and concentration as described in this report.

Keywords

Safety, Cosmetics, Glyceryl Dilaurate, Glyceryl Diarachidate, Glyceryl Dibehenate, Glyceryl Dierucate, Glyceryl Dihydroxystearate, Glyceryl Diisopalmitate, Glyceryl Diisostearate, Glyceryl Dilinoleate, Glyceryl Dioleate, Glyceryl Diricinoleate, Glyceryl Dipalmitate, Glyceryl Dipalmitoleate, Glyceryl Distearate, Glyceryl Palmitate Lactate, Glyceryl Stearate Citrate, Glyceryl Stearate Lactate, Glyceryl Stearate Succinate

The Expert Panel for Cosmetic Ingredient Safety first issued a final report on the safety of glyceryl diesters in 2002, with an insufficient data conclusion.¹ Subsequently, the necessary data were received, and in 2007, the Expert Panel published an amended final report on the safety of the glyceryl diester ingredients (listed below).² The Expert Panel concluded that these ingredients are safe as cosmetic ingredients in the present practices of use and concentrations described in the safety assessment provided that the content of 1,2-diesters is not high enough to induce epidermal hyperplasia. Glyceryl Dimyristate was originally a part of this group, but has since been reviewed with Myristic Acid ingredients, and is therefore not included in this rereview.

Glyceryl Dilaurate
Glyceryl Diarachidate
Glyceryl Dibehenate
Glyceryl Dierucate
Glyceryl Dihydroxystearate
Glyceryl Diisopalmitate
Glyceryl Diisostearate
Glyceryl Dilinoleate
Glyceryl Dioleate
Glyceryl Diricinoleate
Glyceryl Dipalmitate
Glyceryl Dipalmitoleate
Glyceryl Distearate
Glyceryl Palmitate Lactate

Glyceryl Stearate Citrate
Glyceryl Stearate Lactate
Glyceryl Stearate Succinate

Because it has been at least 15 years since the amended final report was published, in accordance with Cosmetic Ingredient Review Procedures, the Expert Panel determined whether the safety assessment should be reopened. At the September 2022 meeting, the Expert Panel considered updated (2022) information regarding product types and ingredient use frequencies as reported by the US Food and Drug Administration (FDA) Voluntary Cosmetic Registration Program (VCRP) database³ and the maximum use concentrations provided in response to the survey conducted by the Personal Care Products Council.⁴ Generally, there has been an increase in frequency of use since the last review in 2007. As of 2022, Glyceryl Distearate and Glyceryl Stearate Citrate were reported to be used in baby products, when there were no

*Cosmetic Ingredient Review Senior Scientific Analyst/Writer

**Expert Panel for Cosmetic Ingredient Safety Member

***Expert Panel for Cosmetic Ingredient Safety Former Member

†Cosmetic Ingredient Review Senior Director

‡Cosmetic Ingredient Review Executive Director

Corresponding Author:

Bart Heldreth, Executive Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.

Email: cirinfo@cir-safety.org

Table 1. 2022 and Historical Frequency and Concentration of Use According to Duration and Exposure.

	Max Conc of Use (%)				Max Conc of Use (%)			
	# of Uses				# of Uses			
	Glyceryl Dibehenate				Glyceryl Diisostearate			
	2022 ³	2002 ²	2022 ⁴	1999 ²	2022 ³	2002 ²	2022 ⁴	1999 ²
Totals ^d	32	NR	I	NR	139	97	.54	18-43
Duration of use								
Leave-on	32	NR	I	NR	138	97	.54	18-43
Rinse-off	NR	NR	NR	NR	I	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	8	NR	NR	NR	NR	NR	NR	NR
Incidental ingestion	I	NR	NR	NR	124	93	.54	43
Incidental inhalation-spray	5 ^a ; 12 ^b	NR	I ^a	NR	3 ^a ; 3 ^b	I; I ^a ; I ^b	NR	18
Incidental inhalation-powder	12 ^b	NR	NR	NR	3 ^b	I ^b	NR	NR
Dermal contact	26	NR	I	NR	15	3	NR	18
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair – non-coloring	I	NR	NR	NR	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	2	NR	NR	NR	NR	I	NR	NR
Mucous membrane	I	NR	NR	NR	124	93	.54	43
Baby products	NR	NR	NR	NR	NR	NR	NR	NR
Glyceryl Dilaurate								
Totals ^d	2022 ³	2002 ²	2022 ⁴	1999 ²	2022 ³	2002 ²	2022 ⁴	1999 ²
	27	35	I-4	.02-5	10	I	NR	.8-2
Duration of use								
Leave-on	26	27	I-4	2-5	10	I	NR	.8-2
Rinse-off	I	8	NR	.02-5	NR	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	NR	NR	2	I	NR	NR	NR
Incidental ingestion	NR	I	NR	NR	NR	NR	NR	NR
Incidental inhalation-spray	22 ^a ; 4 ^b	8 ^a ; 13 ^b	NR	5 ^a ; 2-4 ^b	5 ^a ; I ^b	NR	NR	2 ^a ; 0.8 ^b
Incidental inhalation-powder	4 ^b	13 ^b	1.5 ^c	2-4 ^b	I; I ^b	NR	NR	0.8 ^b
Dermal contact	27	34	I-4	.02-5	10	I	NR	.8-2
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair – non-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous membrane	NR	4	NR	.02	NR	NR	NR	NR
Baby products	NR	NR	NR	NR	NR	NR	NR	NR
Glyceryl Dipalmitate								
Totals ^d	2022 ³	2002 ²	2022 ⁴	1999 ²	2022 ³	2002	2022 ⁴	1999 ²
	NR	NR	I.I	NR	16	NR	.05-4.4	.00003-7
Duration of use								
Leave-on	NR	NR	I.I	NR	14	NR	.05-4.4	.00003-7
Rinse-off	NR	NR	NR	NR	2	NR	.3-2.2	.0003-6
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR

(continued)

Table I. (continued)

	Glyceryl Dipalmitate				Glyceryl Distearate			
	2022 ³	2002 ²	2022 ⁴	1999 ²	2022 ³	2002	2022 ⁴	1999 ²
Totals ^d	NR	NR	1.1	NR	16	NR	.05-4.4	.00003-7
Exposure type								
Eye area	NR	NR	NR	NR	2	NR	2.3	.003-0.5
Incidental ingestion	NR	NR	NR	NR	1	NR	NR	7
Incidental inhalation-spray	NR	NR	NR	NR	6 ^a ; 2 ^b	NR	2.9 ^a	.00003-7 ^a ; .2-7 ^b
Incidental inhalation-powder	NR	NR	1.1 ^c	NR	2 ^b	NR	.22-4.4 ^b	.2-7 ^b
Dermal contact	NR	NR	1.1	NR	12	NR	.05-4.4	.00003-7
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair – non-coloring	NR	NR	NR	NR	3	NR	.3-.55	6
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	.02
Mucous membrane	NR	NR	NR	NR	1	NR	NR	7
Baby products	NR	NR	NR	NR	NR	NR	.55-1.1	NR
Glyceryl Stearate Citrate								
Totals ^d	2022 ³	2002 ²	2022 ⁴	1999 ²	2022 ³	2002 ²	2022 ⁴	1999 ²
	164	NR	.5-4	NR	NR	NR	NR	5
Duration of use								
Leave-on	142	NR	.5-4	NR	NR	NR	NR	5
Rinse-off	21	NR	NR	NR	NR	NR	NR	NR
Diluted for (bath) use	1	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	6	NR	1.2	NR	NR	NR	NR	NR
Incidental ingestion	1	NR	NR	NR	NR	NR	NR	NR
Incidental inhalation-spray	1;53 ^a ; 61 ^b	NR	NR	NR	NR	NR	NR	5 ^a ; 5 ^b
Incidental inhalation-powder	61 ^b ; 4 ^c	NR	.5-2 ^c	NR	NR	NR	NR	5 ^b
Dermal contact	157	NR	.5-4	NR	NR	NR	NR	5
Deodorant (underarm)	4 ^a	NR	NR	NR	NR	NR	NR	5 ^a
Hair – non-coloring	6	NR	NR	NR	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous membrane	6	NR	NR	NR	NR	NR	NR	NR
Baby products	5	NR	2	NR	NR	NR	NR	NR
Glyceryl Stearate Succinate								
Totals ^d	2022 ³	2002 ²	2022 ⁴	1999 ²				
	1	NR	NR	NR				
Duration of use								
Leave-on	1	NR	NR	NR	NR	NR	NR	NR
Rinse-off	NR	NR	NR	NR	NR	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental inhalation-spray	NR	NR	NR	NR	NR	NR	NR	NR
Incidental inhalation-powder	NR	NR	NR	NR	NR	NR	NR	NR
Dermal contact	1	NR	NR	NR	NR	NR	NR	NR

(continued)

Table 1. (continued)

	Glyceryl Stearate Succinate			
	2022 ³	2002 ²	2022 ⁴	1999 ²
Totals ^d	I	NR	NR	NR
Deodorant (underarm)	NR	NR	NR	NR
Hair – non-coloring	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR
Nail	NR	NR	NR	NR
Mucous membrane	NR	NR	NR	NR
Baby products	NR	NR	NR	NR

^aIt is possible these products are sprays, but it is not specified whether the reported uses are sprays.

^bNot specified whether a spray or a powder, but it is possible the use can be as a spray or a powder; therefore, the information is captured in both categories.

^cIt is possible these products are powders, but it is not specified whether the reported uses are powders.

^dBecause each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses. NR, not reported.

Table 2. Ingredients Not Reported to Be in Use (2022).^{3,4}

Glyceryl Diarachidate
Glyceryl Dierucate
Glyceryl Dihydroxystearate
Glyceryl Diisopalmitate
Glyceryl Dilinoleate
Glyceryl Diricinoleate
Glyceryl Dipalmitoleate
Glyceryl Palmitate Lactate

reported uses for glyceryl diesters in this product category previously. Glyceryl Stearate Citrate, which had no reported uses in the original report, is reported to have 164 uses, at a maximum concentration of use of 4% in non-spray moisturizing products, in 2022. Additionally, although the number of reported uses of Glyceryl Diisostearate in lipstick increased, the maximum reported concentrations of use for this product category significantly decreased, from 43% in 1999 to .54% in 2022. The cumulative frequency and concentration of use data are presented in Table 1. Ingredients with no reported use are listed in Table 2.

An extensive search of the world's literature was performed for studies dated 2002 forward, and new data were found.⁵⁻²⁷ The Expert Panel considered new chronic toxicity,^{14,18} developmental and reproductive toxicity,¹⁹⁻²¹ and carcinogenicity/tumor promotion studies.²²⁻²⁵ In addition to these studies having negative results, the FDA-approved use of Glyceryl Dibehenate and Glyceryl Distearate as inactive ingredients in oral capsule formulations,²⁶ as well as the approved use of diacylglycerol oil and diglycerides as food additives, reassured the Expert Panel of safety.²⁷

The Expert Panel reviewed 2022 frequency and concentration of use data, in addition to any new, available, relevant

safety data, and reaffirmed the 2007 conclusion regarding the safety of glyceryl diesters in cosmetics.

Author's Note

Unpublished sources cited in this report are available from the Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.

Author Contributions

The articles in this supplement were sponsored by the Cosmetic Ingredient Review.

Declaration of Conflicting Interest

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review. The Cosmetic Ingredient Review is financially supported by the Personal Care Products Council.

References

1. Bergfeld WF, Belsito DV, Klaasen CD, et al. Final report of the cosmeitic ingredient review expert panel. Safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate,

- glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate. 2002, Available from CIR. <https://www.cir-safety.org/ingredients>
2. Andersen FA. ed. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate. *Int J Toxicol.* 2007;26 (Suppl 3):1-30.
 3. U.S. Food and Drug Administration Center for Food Safety & Applied Nutrition (CFSAN). Voluntary cosmetic registration Program - Frequency of use of cosmetic ingredients (VCRP). Obtained under the freedom of information act from CFSAN; requested as "Frequency of use data" January 4, 2022; Received January 11, 2022. 2022.
 4. Personal Care Products Council. Concentration of use by FDA product category: Glyceryl diesters. Unpublished data submitted by the Personal Care Products Council on July 7, 2022. 2022.
 5. Frank JA, Yushchenko DA, Hodson DJ, et al. Photoswitchable diacylglycerols enable optical control of protein kinase C. *Nat Chem Biol.* 2016;12(9):755-762.
 6. Yamaguchi Y, Shirai Y, Matsubara T, et al. Phosphorylation and up-regulation of diacylglycerol kinase gamma via its interaction with protein kinase C gamma. *J Biol Chem.* 2006;281(42): 31627-31637.
 7. Lo S-K, Tan C-P, Long K, Yusoff MSA, Lai O-M. Diacylglycerol oil—properties, processes and products: a review. *Food Bioproc Tech.* 2008;1(3):223-233.
 8. Takase H. Metabolism of diacylglycerol in humans. *Asia Pac J Clin Nutr.* 2007;16(Suppl 1):398-403.
 9. Wertz PW. Epidermal lipids. *Semin Dermatol.* 1992;11(2): 106-113.
 10. Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. *Dermatoendocrinol.* 2009;1(2):68-71.
 11. Sanzo KM. Re: GRAS Notice No. GRN 000914. <https://www.fda.gov/media/148683/download>. Last Updated March 15, 2021. Accessed June 30, 2022.
 12. Lee WJ, Zhang Z, Lai OM, Tan CP, Wang Y. Diacylglycerol in food industry: Synthesis methods, functionalities, health benefits, potential risks and drawbacks. *Trends Food Sci Technol.* 2020;97:114-125.
 13. Zeng N, Gao X, Hu Q, et al. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. *Int J Nanomedicine.* 2012;7:3703-3718.
 14. Morita O, Tamaki Y, Kirkpatrick JB, Chengelis CP. Safety assessment of heated diacylglycerol oil: Subchronic toxicity study in rats. *Food Chem Toxicol.* 2008;46(8):2748-2757.
 15. Honda H, Kawamoto T, Doi Y, et al. Alpha-linolenic acid-enriched diacylglycerol oil does not promote tumor development in tongue and gastrointestinal tract tissues in a medium-term multi-organ carcinogenesis bioassay using male F344 rat. *Food Chem Toxicol.* 2017;106(Pt A):185-192.
 16. Kasamatsu T, Ogura R, Ikeda N, et al. Genotoxicity studies on dietary diacylglycerol (DAG) oil. *Food Chem Toxicol.* 2005; 43(2):253-260.
 17. Australian industrial Chemicals introduction Scheme (AICIS). *Full Public Report: Docosanoic Acid, Ester with 1,2,3-Propanetriol (File No.: LTD/2050).* https://www.industrialchemicals.gov.au/sites/default/files/LTD2050_Public_Report_PDF.pdf. Sydney, Australia. Last Updated September 2018. Accessed July 29, 2022.
 18. Bushita H, Ito Y, Saito T, et al. A 90-day repeated-dose toxicity study of dietary alpha linolenic acid-enriched diacylglycerol oil in rats. *Regul Toxicol Pharmacol.* 2018;97:33-47.
 19. Morita O, Knapp JF, Tamaki Y, Nemec MD, Varsho BJ, Stump DG. Safety assessment of dietary diacylglycerol oil: a two-generation reproductive toxicity study in rats. *Food Chem Toxicol.* 2008;46(9):3059-3068.
 20. Bushita H, Liu S, Ohta T, et al. Effects of dietary alpha-linolenic acid-enriched diacylglycerol oil on embryo/fetal development in rats. *Regul Toxicol Pharmacol.* 2018;98:108-114.
 21. Chengelis CP, Kirkpatrick JB, Marit GB, Morita O, Tamaki Y, Suzuki H. A chronic dietary toxicity study of DAG (diacylglycerol) in Beagle dogs. *Food Chem Toxicol.* 2006;44(1): 81-97.
 22. Chengelis CP, Kirkpatrick JB, Bruner RH, et al. A 24-month dietary carcinogenicity study of DAG in mice. *Food Chem Toxicol.* 2006;44(1):122-137.
 23. Chengelis CP, Kirkpatrick JB, Bruner RH, et al. A 24-month dietary carcinogenicity study of DAG (diacylglycerol) in rats. *Food Chem Toxicol.* 2006;44(1):98-121.
 24. Ichihara T, Yoshino H, Doi Y, et al. No enhancing effects of diacylglycerol oil on tumor development in a medium-term multi-organ carcinogenesis bioassay using male F344 rats. *Food Chem Toxicol.* 2008;46(1):157-167.
 25. Honda H, Fujita Y, Hayashi A, Ikeda N, Ito Y, Morita O. Genotoxicity evaluation of alpha-linolenic acid-diacylglycerol oil. *Toxicol Rep.* 2016;3:716-722.
 26. U.S. Food and Drug Administration (FDA). *Inactive Ingredients in Approved Drug Products Search Database.* <https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm>. Last Updated 2022. Accessed March 08, 2022.
 27. European Food Safety Authority (EFSA). Opinion on the re-evaluation of mono- and diglycerides of fatty acids (E 471) as food additive in foods for infants below 16 weeks of age and follow-up of their re-evaluation as food additives for uses in foods for all population groups. *EFSA J.* 2021;19(11):6885.